Aimovig® (erenumab) dosing and administration
This page/content is for Great Britain healthcare professionals only. If you require information for Northern Ireland please refer to the Northern Ireland electronic medicines compendium (emc).
Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.1
Aimovig offers convenient administration every four weeks, with no loading dose1
After proper training, Aimovig can be self-administered at home by subcutaneous injection using an auto-injector or a pre-filled syringe.1
Aimovig can be administered as a 70 mg or 140 mg dose every 4 weeks1
A 70 mg dose is administered as one 70 mg single-use, pre-filled pen/syringe.
A 140 mg dose is administered as either one 140 mg single-use pre-filled pen/syringe, or as two 70 mg single-use, pre-filled pens/syringes1
No loading dose1
No effect on exposure to co-administered medical products expected1
No interaction with oral contraceptives (ethinyl estradiol/norgestimate) or sumatriptan was observed in the studies with healthy volunteers1
No contraindications other than hypersensitivity to the active substance or to any of the excipients of Aimovig1
Things you need to know about the Aimovig autoinjector pen2
Injecting Aimovig takes about 15 seconds
The needle is hidden inside the safety guard
It must be stored in the refrigerator (at 2–8°C) in the original carton to protect it from light
Aimovig pens must not be shaken or frozen
Once out of the refrigerator, it should be kept at room temperature (up to 25°C) in the original carton, and it must be used within 7 days. Do not put Aimovig back in the refrigerator once it has been removed
Throw it away if it has been at room temperature for more than 7 days
Leave the pen at room temperature for at least 30 minutes before injecting
Your guide to Aimovig
Your guide to Aimovig
A guide for patients prescribed Aimovig to provide them with important information about what Aimovig is, who it is for, how it works and what to expect during treatment.
References
Aimovig® (erenumab) Summary of Product Characteristics.
Aimovig® (erenumab) Package leaflet: Information for the user.
UK | October 2024 | FA-11214744
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.